Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did not achieve its primary endpoint.

30 Mar 2015

CFDA accepts WuXi MedImmune's novel anti-IL6 monoclonal antibody IND application for review

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that an Investigational New Drug (IND) application for WuXi MedImmune's novel anti-IL6 monoclonal antibody for rheumatoid arthritis has been accepted for review by the China Food and Drug Administration.

29 Mar 2015

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao.

26 Mar 2015

Autoimmune disease forum to be held in Tampa on March 28, 2015

The "What Every American Needs to Know About Autoimmune Disease" public forum arrives in Tampa on Saturday, March 28th. The program will begin at 9:30am and end at 3:30pm.

26 Mar 2015

Hip replacement procedure alleviates pain, improves function in young JIA patients

Hip replacement is often performed in patients with juvenile arthritis when their joints have been severely damaged by the disease.

25 Mar 2015

Previous joint pain, diabetes and overall health status may predict arthritis pain

Diabetes and previous joint pain, along with a patient's overall physical health status, may predict arthritis pain with nearly 100 percent accuracy, in new research presented today at the 2015 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).

24 Mar 2015

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher Pharmaceuticals Inc. today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma for moderate to severe plaque psoriasis and rheumatoid arthritis.

23 Mar 2015

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.

23 Mar 2015

Discovery raises potential of blood test that can help diagnose osteoarthritis, rheumatoid

The first blood test for osteoarthritis could soon be developed, thanks to research by the University of Warwick.

20 Mar 2015

Janssen announces acquisition of XO1

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab.

19 Mar 2015

UVA researcher identifies potential therapeutic target for myotonic muscular dystrophy

A doctor who was one of the discoverers of the gene responsible for myotonic muscular dystrophy has now identified a therapeutic that could modify progression of muscle damage and muscle dysfunction associated with the disease - issues that cause patients significant disability and deterioration in quality of life.

19 Mar 2015

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Samsung Bioepis Co., Ltd., today announced that the Marketing Authorization Application (MAA) for SB2, its Remicade (Infliximab) biosimilar candidate, has been submitted to the European Medicines Agency (EMA).

13 Mar 2015

Researcher shares study results of periodontitis and RA at IADR General Session

Today at the 93rd General Session and Exhibition of the International Association for Dental Research, researcher Sheila Arvikar, Massachusetts General Hospital, Boston, USA, will present a study titled "Inflammation in the Mouth and Joints in Rheumatoid Arthritis."

13 Mar 2015

TSRI chemists develop innovative method for building new drug molecules

Chemists at The Scripps Research Institute have developed a broadly useful technique for building new drug molecules and other chemical products.

12 Mar 2015

TSRI researchers create picture of whole dynein-dynactin structure

A team led by scientists at The Scripps Research Institute has determined the basic structural organization of a molecular motor that hauls cargoes and performs other critical functions within cells.

12 Mar 2015

M-MDSCs may be effective in treating arthritis in humans

Using a mouse model of rheumatoid arthritis, scientists have discovered that a form of cellular immunotherapy by intravenous administration of monocytic myeloid-derived suppressor cells, or M-MDSCs, might be an effective treatment for the disease in humans.

9 Mar 2015

TSRI researchers show how ABC transporters cause multidrug resistance

Cancer patients fear the possibility that one day their cells might start rendering many different chemotherapy regimens ineffective. This phenomenon, called multidrug resistance, leads to tumors that defy treatment.

3 Mar 2015

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets.

1 Mar 2015

Pharmacyclics completes toxicology studies of BTK inhibitor in RA

Pharmacyclics, Inc. today announced that longer-term toxicology studies for its newly developed Bruton's tyrosine kinase (BTK) inhibitor for rheumatoid arthritis, or RA, have been completed.

28 Feb 2015

TSRI scientists show how to target weak spots of Marburg virus with future treatments

Marburg virus is Ebola's deadly cousin. The virus is up to 90 percent lethal—and doctors are desperate for tools to fight it.

27 Feb 2015

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

CFDA accepts WuXi MedImmune's novel anti-IL6 monoclonal antibody IND application for review

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Autoimmune disease forum to be held in Tampa on March 28, 2015

Hip replacement procedure alleviates pain, improves function in young JIA patients

Previous joint pain, diabetes and overall health status may predict arthritis pain

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Discovery raises potential of blood test that can help diagnose osteoarthritis, rheumatoid

Janssen announces acquisition of XO1

UVA researcher identifies potential therapeutic target for myotonic muscular dystrophy

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Researcher shares study results of periodontitis and RA at IADR General Session

TSRI chemists develop innovative method for building new drug molecules

TSRI researchers create picture of whole dynein-dynactin structure

M-MDSCs may be effective in treating arthritis in humans

TSRI researchers show how ABC transporters cause multidrug resistance

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Pharmacyclics completes toxicology studies of BTK inhibitor in RA

TSRI scientists show how to target weak spots of Marburg virus with future treatments

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in